As filed with the Securities and Exchange Commission on April 23, 1998.
REGISTRATION NO. 333-_______
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
---------------------------
HENLEY HEALTHCARE, INC.
(Exact name of registrant ass specified in its charter)
<TABLE>
<S> <C> <C>
TEXAS 3842 76-0335587
(State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer
incorporation or organization) Classification Code Number) Identification Number)
</TABLE>
120 INDUSTRIAL BLVD.
SUGAR LAND, TEXAS 77478
(281) 276-7000
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
DAN D. SUDDUTH WITH COPIES TO:
HENLEY HEALTHCARE, INC. ROBERT G. REEDY
120 INDUSTRIAL BLVD. PORTER & HEDGES, L.L.P.
SUGAR LAND, TEXAS 77478 700 LOUISIANA, 35TH FLOOR
(281) 276-7000 HOUSTON, TEXAS 77002-2370
(Name and address, including zip code, and telephone (713) 226-0600
number, including area code, of agent for service)
--------------------------------
Approximate date of commencement of proposed sale to the public: As soon
as practicable after the Registration Statement becomes effective.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box.[ ]
If any of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, other than securities offered only in connection with a dividend or
interest reinvestment plan, please check the following box.|X|
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering.[ ] ________________
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering.[ ] _____________
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box.[ ]
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
========================================== ============= ========================= ========================== ==================
TITLE OF EACH CLASS OF AMOUNT TO PROPOSED MAXIMUM OFFERING PROPOSED MAXIMUM AGGREGATE AMOUNT OF
SECURITIES TO BE REGISTERED BE REGISTERED PRICE PER SHARE(1) OFFERING PRICE(1) REGISTRATION FEE(1)
========================================== ============= ========================= ========================== ==================
<S> <C> <C> <C>
Common Stock, par value $.01 per share (2) 862,066 $ 6.6875 $ 5,765,066.38 $ 1,701
Common Stock, par value $.01 per share (3) 30,000 $ 6.6875 $ 200,625.00 $ 59
Common Stock, par value $.01 per share (4) 200,000 $ 6.6875 $ 1,337,500.00 $ 395
Common Stock, par value $.01 per share (5) 40,000 $ 6.6875 $ 267,500.00 $ 79
Common Stock, par value $.01 per share 2,048,148 $ 6.6875 $13,696,989.75 $ 4,041
TOTAL 3,180,214 $ 6.6875 $21,267,681.13 $ 6,274
========================================== ============= ========================= ========================== ==================
</TABLE>
(1) Pursuant to Rule 457(c), the registration fee is calculated based on the
average of the high and low prices for the Common Stock, as reported by The
Nasdaq SmallCap Market on April 16, 1998, of $6.6875 per share.
(2) Issuable upon conversion of 2,500 shares of Series A Preferred Stock, par
value $.10 per share (the "Series A Preferred Stock"). The Series A
Preferred Stock has a floating conversion price calculated by dividing the
$1,000 stated value of the shares being converted by an amount equal to the
lesser of (i) 75% of the average closing bid price of the Common Stock
during the period of five trading days immediately preceding the conversion
date, or (ii) 100% of the closing bid price of the Common Stock on the
original issuance date ($6.50 for 1,825 shares of the Series A Preferred
Stock sold on March 13, 1998, and $6.375 for 675 shares of Series A
Preferred Stock sold on April 9, 1998); provided, however, that such
conversion price shall not be less than $2.90. For the purpose of
estimating the number of shares of Common Stock to be included in this
Registration Statement, the Company calculated the maximum number of shares
of Common stock issuable in connection with the conversion of the Company's
Series A Preferred Stock using the minimum conversion price of the Series A
Preferred Stock of $2.90. This would result in the issuance of 862,066
shares of Common Stock. In addition to the estimated number of shares set
forth in the table, the amount to be registered includes a presently
indeterminate number of shares issuable upon conversion of or otherwise in
respect of the Series A Preferred Stock as such number may be adjusted as a
result of stock split, stock dividend and antidilution provisions
(including floating rate conversion prices) in accordance with Rule 416.
(3) These 30,000 shares of Common Stock are issuable, at the Company's option,
for payment of dividends on the Series A Preferred Stock, and are estimated
to be sufficient to allow the Company to meet its obligation to pay
dividends for one year.
(4) Issuable upon exercise of warrants for a total of 200,000 shares comprised
of (i) four groups of warrants for 36,500 shares each at exercise prices of
$7.125, $8.194, $8.550 and $9.619, respectively, and (ii) four groups of
warrants for 13,500 shares each at exercise prices of $6.375, $7.331, $7.65
and $8.606, respectively. Also includes an indeterminate number of shares
issuable on exercise of the warrants as adjusted pursuant to antidilution
provisions of such warrants in accordance with Rule 416.
(5) Issuable upon exercise of an option for 40,000 shares at an exercise price
of $4.00 per share. Also includes an indeterminate number of shares
issuable on exercise of the option as adjusted pursuant to antidilution
provisions of such options in accordance with Rule 416.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
MAY DETERMINE.
<PAGE>
PROSPECTUS HENLEY HEALTHCARE, INC.
3,180,214 SHARES
COMMON STOCK
This Prospectus relates to 3,180,214 shares of common stock, par value
$.01 per share (the "Common Stock"), of Henley Healthcare, Inc., a Texas
corporation (the "Company"), which shares will be offered for resale from time
to time by certain stockholders of the Company (the "Selling Stockholders"). Of
these shares, 1,092,066 relate to the Company's private placement of its Series
A Preferred Stock, par value $.10 per share (the "Series A Preferred Stock"),
that was completed in two separate closings held on March 13, 1998, and April 9,
1998 (the "Private Placement"). The 2,500 shares of Series A Preferred Stock
sold in the Private Placement are convertible into a maximum of 862,066 shares
of Common Stock (subject to adjustment) (the "Conversion Shares"). The
purchasers in the Private Placement also received warrants (the "Warrants") to
purchase up to 200,000 shares of Common Stock (the "Warrant Shares"). Also
included in this Prospectus are 30,000 shares of Common Stock which the Company
may, at its option, issue to the purchasers in the Private Placement as
dividends on the Series A Preferred Stock (the "Dividend Shares"). It is
estimated that the Dividend Shares will be sufficient to meet the Company's
obligation to pay dividends for one year. In addition, 88,148 shares are
comprised of 48,148 shares of Common Stock (the "Med-Quip Shares") issued in
connection with the Company's purchase of Med-Quip, Inc., and 40,000 shares of
Common Stock (the "Option Shares") issuable upon exercise of options to purchase
that number of shares (the "Options") issued to certain Selling Stockholders in
exchange for services rendered to the Company. The remaining shares registered
hereby are comprised of 2,000,000 shares of Common Stock issued to Maxxim
Medical, Inc. ("Maxxim") upon conversion by Maxxim of $4 million of the
principal amount of a convertible note of the Company issued to Maxxim on April
30, 1996 (the "Maxxim Note"), 500,000 of which have been transferred to and are
owned by certain institutional investors (the "Institutional Shares"), and
1,500,000 of which are still owned of record by Maxxim (the "Maxxim Shares").
The Conversion Shares, the Warrant Shares, the Dividend Shares, the Med-Quip
Shares, the Option Shares, the Institutional Shares and the Maxxim Shares are
sometimes herein collectively referred to as the "Shares."
Pursuant to this Prospectus, the Shares may be offered by the Selling
Stockholders, or by certain pledgees, donees, transferees or other successors in
interest to the Selling Stockholders, from time to time in transactions on The
Nasdaq SmallCap Market ("Nasdaq") or such other exchange or market as the Common
Stock may be listed from time to time, in privately negotiated transactions, or
by a combination of such methods of sale, at fixed prices that may be changed,
at market prices prevailing at the time of sale, at prices related to such
prevailing market prices or at negotiated prices. The Selling Stockholders may
effect such transactions by selling the Shares to or through broker-dealers, and
such broker-dealers may receive compensation in the form of discounts,
concessions or commissions from the Selling Stockholders or the purchasers of
the Shares for whom such broker-dealers may act as agent or to whom they sell as
principal or both (which compensation to a particular broker-dealer might be in
excess of customary commissions). See "Selling Stockholders" and "Plan of
Distribution."
Other methods by which the Shares may be sold include, without limitation:
(i) transactions which involve cross or block trades or any other transaction
permitted by the Nasdaq or other trading markets, (ii) "at the market" to or
through market makers or into an existing market for the Common Stock, (iii) in
other ways not involving market makers or established trading markets, including
direct sales to purchasers or sales effected through agents, (iv) through
transactions in options or swaps or other derivatives (whether exchange-listed
or otherwise), (v) through short sales, or (vi) any combination of any such
methods of sale. The Selling Stockholders may also enter into option or other
transactions with broker-dealers which require the delivery to such broker
dealers of the Common Stock offered hereby, which Common Stock such
broker-dealers may resell pursuant to this Prospectus. The Selling Shareholders
may also make sales pursuant to Rule 144 under the Securities Act of 1933, as
amended (the "Securities Act"), if such exemption from registration is otherwise
available.
None of the proceeds from the sale of the Shares by the Selling
Stockholders will be received by the Company. However, the Company will receive
up to $1,786,799 upon the exercise of the Options and Warrants. The Company has
agreed to bear certain expenses (other than any underwriting discounts and
selling commissions and any fees and disbursements of counsel for the Selling
Stockholders not specifically provided for by the parties), estimated to be
approximately $51,274, in connection with the registration and sale of the
Shares being offered by the Selling Stockholders. Pursuant to Registration
Rights Agreements with certain Selling Stockholders, the Company has agreed to
indemnify certain of the Selling Stockholders and each underwriter against
certain liabilities, including certain liabilities under the Securities Act, or
will contribute to payments such Selling Stockholders or underwriters may be
required to make in respect of certain losses, claims, damages or liabilities.
The shares of Common Stock are quoted on the Nasdaq under the symbol
"HENL." On April 16, 1998, the last reported sale price of the Common Stock was
$6.6875 per share.
SEE "RISK FACTORS" BEGINNING ON PAGE 4 FOR A DISCUSSION OF CERTAIN FACTORS THAT
SHOULD BE CONSIDERED BY PROSPECTIVE INVESTORS.
---------------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
The date of this Prospectus is April 23, 1998.
<PAGE>
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith, files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information can be inspected and copied at the public
reference facilities of the Commission at Room 1024, Judiciary Plaza, 450 Fifth
Street, N.W., Washington, D.C. and at the Commission's regional offices at the
Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, Illinois
60661-2511 and 7 World Trade Center, Suite 1300, New York, 10048. Copies of such
material may also be obtained from the Public Reference Section of the
Commission at Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549,
at prescribed rates. In addition, the Commission maintains a World Wide Web site
at http://www.sec.gov that contains reports, proxy and information statements,
and other information regarding registrants that file electronically with the
Commission.
The Company has filed with the Commission a Registration Statement on Form
S-3 (including any amendments thereto, the "Registration Statement") under the
Securities Act of 1933, as amended (the "Securities Act") with respect to the
shares of Common Stock offered hereby. This Prospectus does not contain all of
the information set forth in the Registration Statement and the exhibits and
schedules thereto. For further information with respect to the Company and the
Common Stock, reference is made to the Registration Statement and the exhibits
and schedules thereto. Statements made in this Prospectus regarding the contents
of any contract or document filed as an exhibit to the Registration Statement
are not necessarily complete and, in each instance, reference is hereby made to
the copy of such contract or document so filed. Each such statement is qualified
in its entirety by such reference.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following are hereby incorporated by reference in this Prospectus:
(1) The Company's Annual Report on Form 10-KSB for the fiscal year
ended December 31, 1997; and
(2) The description of the Company's Common Stock contained in the
Company's Registration Statement on Form 8-A effective June 26,
1996 (Commission File No. 000-28566), including any amendments or
reports filed for the purpose of updating such description.
All documents filed by the Company pursuant to Sections 13(a), 13(c), 14
or 15(d) of the Exchange Act after the date of this Prospectus and before the
termination of the offering covered hereby will be deemed to be incorporated by
reference in this Prospectus and to be a part hereof from the date of filing
such documents. Any statement contained in a document incorporated or deemed to
be incorporated by reference in this Prospectus shall be deemed to be modified
or superseded for purposes of this Prospectus to the extent that a statement
contained in this Prospectus or in any other subsequently filed document that
also is or is deemed to be incorporated by reference modifies or replaces such
statement.
The Company will provide, without charge and on oral or written request,
to each person to whom this Prospectus is delivered, a copy of any or all of the
documents incorporated by reference in this Prospectus other than exhibits to
such documents, unless such exhibits are specifically incorporated by reference
into the information that this Prospectus incorporates. In addition, a copy of
the Company's most recent annual report to stockholders will be promptly
furnished, without charge and on oral or written request, to such persons. All
such requests should be directed to Henley Healthcare, Inc., 120 Industrial
Boulevard, Sugar Land, Texas 77478, Attention: Dan D. Sudduth, Chief Financial
Officer (telephone (281) 276-7000).
THE COMPANY
Henley Healthcare, Inc. (the "Company"), a leader in the growing pain
management industry, develops, manufactures and distributes products and related
accessories used in the control of acute or chronic pain. The Company's
diversified line of non-invasive physical medicine and rehabilitation products
are used in the treatment of disabilities or injuries with therapeutic exercise
and the application of various heat, fluidotherapy, traction, ultrasound or
other modalities. The Company is also seeking approval from the United States
Food and Drug Administration (the "FDA") on its MicroLight 830(TM), a hand-held,
low-energy (non-surgical) laser for the treatment of repetitive stress injuries
such as carpal tunnel syndrome. The Company's principal executive offices are
located at 120 Industrial Boulevard, Sugar Land, Texas 77478, and its telephone
number is (281) 276-7000.
2
<PAGE>
RECENT DEVELOPMENTS
On March 6, 1998, the Company announced that it has entered into a
definitive purchase agreement with Delft Instruments (AEX General: DELFT), an
international conglomerate with operations in medical, defense, aerospace,
industrial and scientific industries, to acquire Enraf-Nonius, its wholly owned
subsidiary. The acquisition will be made for cash and notes. Additional details
regarding the transaction will be disclosed upon completion of the acquisition
tentatively expected in April 1998. The acquisition is subject to approval by
the board of directors of both companies and the Netherlands regulatory boards.
Enraf-Nonius is a worldwide leader in electrotherapy and ultrasound
products based in Delft, Netherlands. Enraf-Nonius has been in business for over
65 years and specializes in the development, manufacture and sale of a complete
line of innovative medical products to the physical therapy and rehabilitation
markets. Enraf-Nonius products are sold worldwide through a network of sales
offices dealers and distributors located in more than 100 countries.
Enraf-Nonius maintains regional offices in Barcelona, Spain, Paris, France,
Solingen, Germany, Bangkok, Thailand and Oudenaarde, Belgium, and reported
revenues in excess of $35 million for its 1997 fiscal year. Enraf's physical
therapy and rehabilitation products include ultra-sound and electrical
stimulation products that complement the Company's existing product lines.
3
<PAGE>
RISK FACTORS
IN EVALUATING THE COMPANY AND ITS BUSINESS, PROSPECTIVE INVESTORS SHOULD
CAREFULLY CONSIDER ALL OF THE INFORMATION SET FORTH IN THIS PROSPECTUS AND
SHOULD GIVE PARTICULAR ATTENTION TO THE FOLLOWING RISK FACTORS.
FUTURE CAPITAL NEEDS; NEED FOR ADDITIONAL FUNDING.
The Company recorded a net loss of $2,124,433 or $.71 per share for the
year ended December 31, 1997 on net sales of $24,257,014. Although sales have
increased in recent periods, there can be no assurance that the Company will be
successful in increasing sales for the long term, or that it will be able to
achieve sustained profitability. Further, although the Company has considerable
working capital, a substantial portion of such working capital consists of
receivables and inventory associated with direct sales. At December 31, 1997,
the Company had approximately $894,000 of additional borrowing authority under
its line of credit. The Company's long-term capital requirements will depend on
many factors, including, but not limited to, revenue from operations, working
capital requirements, product development expenses and capital expenditures. The
Company may also require substantial additional capital for it to effectuate its
acquisition and growth strategy. Historically, the Company has relied upon the
sale of equity securities and bank financing as sources of funding to finance
acquisitions. To the extent that existing resources are insufficient to fund the
Company's acquisition activities in the short or long term, the Company will
need to raise additional funds through public or private financings. It is
anticipated that the Company will require additional capital to complete the
acquisition of Enraf-Nonius and any future acquisitions. No assurance can be
given that additional financing will be available or that, if available at all,
the terms of such financing will be favorable to the Company or to its
shareholders without substantial dilution of their ownership and rights. If
adequate funds are not available to satisfy either short- or long-term
requirements, the Company may be required to curtail its acquisition and growth
strategy significantly.
MANAGEMENT OF GROWTH; NEED TO ESTABLISH INFRASTRUCTURE; ADDITIONAL PERSONNEL.
Over the last three years, the Company has completed eleven acquisitions,
and this rapid growth has placed, and is expected to continue to place, a
significant strain on the Company's managerial, operational and financial
resources. To manage its growth, the Company must continue to implement and
improve its operational and financial systems and to expand, train and manage
its employee base. There can be no assurance that the Company has made adequate
allowances for the costs and risks associated with this expansion, that the
Company's systems, procedures or controls will be adequate to support the
Company's operations or that the Company's management will be able to achieve
the rapid execution necessary to successfully offer the Company's products and
services and implement its business plan. The Company's future operating results
will also depend on its ability to expand its support organization commensurate
with the growth of its business and to integrate newly acquired operations. Any
failure by the Company's management to effectively anticipate, implement and
manage the changes required to sustain the Company's growth would have a
material adverse effect on the Company's business, financial condition and
results of operations. There can be no assurance that the Company will be able
to effectively manage such change.
INCREASE IN INVENTORY AND TRADE ACCOUNTS RECEIVABLE.
The Company has rapidly increased the amount of direct sales. Because
payment is in some cases received directly from health insurance carriers which
require a substantial amount of time (averaging approximately 120 days) to
approve reimbursement for sale and rental of products, the Company's accounts
receivable have grown significantly in recent months. As a result of an
extensive review of its third party billing operations conducted by the Company
during 1997, the Company revised its estimates of collectibility of the accounts
receivable for such accounts and increased its reserve for doubtful accounts by
approximately $2,000,000. The Company has added personnel to deal with
collections and record keeping and has established reserves, which it believes
are adequate, for uncollectible receivables and inventory shrinkage.
Nevertheless, there can be no assurances that it can continue to generate
increasing sales, or that all the sales can be collected.
VOLATILE MARKETS/DEPENDENCE ON NEW PRODUCTS.
The pain management market is a relatively mature and competitive market,
subject to significant fluctuations in profitability caused by foreign
competition, questions of therapeutic efficacy and governmental regulation and
private rates of reimbursement. The rehabilitation market is an evolving and
fragmented market with a number of different companies offering competing
treatments without any clear indication of preference among treating clinicians.
There can be no assurance that the Company will ever be able to capture a
significant portion of the pain management market or that it can establish a
significant position in the rehabilitation market.
4
<PAGE>
COMPETITION.
Competition in the industry from other pain management and rehabilitation
device companies, as well as from pharmaceutical companies, and biotechnology
companies, is intense. Some of the companies with which the Company competes
have significantly greater resources, established direct sales organizations and
greater experience in the marketing and sales of products through direct
distribution. Although the Company believes that the broad range of
rehabilitation products it sells distinguishes it from such competitors, there
can be no assurance that the Company will be able to compete effectively.
LIMITATIONS ON REIMBURSEMENT.
Many of the Company's products are sold or rented on prescription and the
sales or rental price is reimbursed to the Company or its dealers by the
patients' insurers. Both private insurers and the United States Government as
the administrator of Medicare and Medicaid will reimburse patients for the cost
of such products based on scheduled rates that they have established. Generally
the Company, and other providers of medical products, attempt to sell and lease
their products at prices approximating these reimbursement rates. Nevertheless,
private and government payers are increasingly vigorous in their attempts to
contain health care costs through limitations on the level of reimbursement and
scrutiny of items submitted for reimbursement. To the extent such private
insurers, Medicare or Medicaid decrease the rate of reimbursement with respect
to any product or line of products, the Company's profit margins and revenues
may be adversely affected.
UNCERTAINTY REGARDING GOVERNMENT HEALTH CARE REFORM.
Several states and the federal government are investigating a variety of
alternatives to reform the health care delivery system and further reduce and
control health care spending. These reform efforts include proposals to limit
spending on health care items and services, limit coverage for new technology,
and limit or control directly the prices health care providers and drug and
device manufacturers may charge for their services and products. The scope and
timing of such reforms cannot be predicted at this time, but if adopted and
implemented, they could have a material adverse effect on the Company.
NEGATIVE PUBLICITY REGARDING TENS.
TENS sales throughout the industry were negatively affected several years
ago by publications questioning the efficacy of TENS for pain relief. Although
two theories have been advanced to explain the mechanism through which TENS
relieves pain, neither theory has conclusive support in scientific literature.
Studies generally indicate that TENS and other modalities offered by the Company
are effective in relieving chronic pain. Nevertheless, there can be no assurance
that contrary studies or publicity regarding TENS or other Company products and
services will not negatively impact sales in the future.
PRODUCT LIABILITY.
Like most producers of medical products, the Company faces the risk of
product liability claims and unfavorable publicity in the event that the use of
its products causes injury or has other adverse effects. Although the Company
has product liability insurance for risks of up to $3,000,000 and has not been
subject to any material claims for product liability, there can be no assurance
that such insurance would prove adequate to cover all potential product claims,
that it will be able to maintain such insurance indefinitely, or that it will be
able to avoid product liability exposure.
PRODUCT RECALLS.
If a device that is designed or manufactured by the Company is found to be
defective, whether due to design or manufacturing defects, to improper use of
the product, or to other reasons, the device may need to be recalled, possibly
at the Company's expense. Furthermore, the adverse effect of a product recall on
the Company might not be limited to the cost of a recall. For example, a product
recall could cause a general investigation of the Company by applicable
regulatory authorities as well as cause other customers to review and
potentially terminate their relationships with the Company. Recalls, especially
if accompanied by unfavorable publicity or termination of customer
relationships, could result in substantial costs, loss of revenues, and a
diminution of the Company's reputation, each of which could have a material
adverse effect on the Company's business, results of operations and financial
condition.
5
<PAGE>
POTENTIAL FLUCTUATIONS IN QUARTERLY RESULTS.
The Company's operating results may fluctuate significantly in the future
as a result of a variety of factors, some of which are outside of the Company's
control. These factors include general economic conditions, specific economic
conditions in the pain management and rehabilitation, seasonal trends in sales,
capital expenditures, new acquisitions and other costs relating to the expansion
of operations, the introduction of new products or services by the Company or
its competitors, the mix of the services sold and the channels through which
those services are sold and pricing changes. As a strategic response to a
changing competitive environment, the Company may elect from time to time to
make certain pricing, service or marketing decisions or acquisitions that could
have a material adverse effect on the Company's business, results of operations
and financial condition. Due to all of the foregoing factors, it is likely that
in some future quarter, the Company's operating results may be below the
expectations of public market analysts and investors. In such event, the price
of the Company's Common Stock would likely be materially adversely affected.
DEPENDENCE ON KEY PERSONNEL.
The Company's performance is substantially dependent on the performance of
its executive officers and key employees all of whom have worked together for a
relatively short period of time. In particular, the services of Michael M.
Barbour and Dan D. Sudduth would be difficult to replace. The Company has
entered into an employment agreement with Mr. Barbour. In addition, the Company
has a $3,000,000 key person life insurance policy on the life of Mr. Barbour;
however, the proceeds of that policy may not be sufficient to compensate the
Company for the loss of Mr. Barbour's services. The Company does not have such
policies in place on any of its other employees. The loss of the services of any
of its executive officers or other key employees could have a material adverse
effect on the business, results of operations or financial condition of the
Company. The Company is heavily dependent upon its ability to attract, retain
and motivate skilled technical and managerial personnel. The Company's future
success also depends on its continuing ability to identify, hire, train and
retain other highly qualified technical and managerial personnel. Competition
for such personnel is intense, and there can be no assurance that the Company
will be able to attract, assimilate or retain other highly qualified technical
and managerial personnel in the future. The inability to attract, hire or retain
the necessary technical and managerial personnel could have a material adverse
effect upon the Company's business, results of operations or financial
condition.
GOVERNMENTAL REGULATION AND FDA APPROVAL.
The development of the Company's MicroLight 830(TM) product and certain of
its other products are subject to extensive and rigorous regulation by the FDA
pursuant to the Federal Food, Drug, and Cosmetic Act (the "FDA Act"), by
comparable agencies in foreign countries, and by state regulatory agencies.
Under the FDA Act, medical devices must receive FDA clearance before they can be
commercially marketed in the United States. The process of obtaining marketing
clearance from the FDA for new products can take a number of years and require
the expenditure of substantial resources, and may involve rigorous pre-clinical
and clinical testing. The time required for completing such testing and
obtaining FDA clearance is uncertain, and there is no assurance that the Company
will have sufficient resources to complete the required testing and regulatory
review process, that such clearances will be granted, or that FDA review will
not involve delays that will adversely affect the Company's ability to
commercialize additional products. Delays or rejections may be encountered based
upon changes in FDA policy during the period of product development and FDA
review of each submitted application. Similar delays may also be encountered in
other countries. Even if regulatory approvals to market a product are obtained
from the FDA, these approvals may entail limitations on the indicated uses of
the product. In addition, as can be expected with any investigational device,
modifications will be made to the Company's products to incorporate and enhance
their functionality and performance based upon new data and design review. There
can be no assurance that the FDA will not request additional information
relating to product improvements, that any such improvements will not require
further regulatory review thereby delaying the testing, approval and
commercialization of the Company's development products, or that ultimately any
such improvements will receive FDA clearance. Product approvals by the FDA can
also be withdrawn due to failure to comply with regulatory standards or the
occurrence of unforseen problems following initial approval. Later discovery of
previously unknown problems with a product, manufacturer, or facility may result
in restrictions on such product or manufacturer, including fines, delays or
suspensions or regulatory clearances, seizures or recalls of products, operating
restrictions and criminal prosecution, and could have a material adverse effect
on the Company. FDA regulations depend heavily on administrative interpretation,
and there can be no assurance that future interpretations made by the FDA or
other regulatory bodies, with possible retroactive effect, will not adversely
affect the Company.
The MicroLight 830(TM), a Class III medical device, has been defined by
the FDA as a "non-significant risk" device. The Company is allowed to conduct
clinical trials under an approved Investigational Device Exemption ("IDE") using
the MicroLight 830(TM). In August 1997, the FDA accepted the Company's Pre-IDE
Clinical Investigation Plan for a multi-center, double-blind, randomized,
clinical study to evaluate the efficacy of the MicroLight 830(TM) in the
treatment of carpel tunnel syndrome ("CTS"). These clinical trials are subject
to IDE regulations, including record keeping, adverse event reporting and other
clinical study requirements. Pursuant to IDE regulations the Company's clinical
researchers are required to be reviewed and approved by an Institutional Review
Board ("IRB") to treat human patients for research purposes. The
6
<PAGE>
objective of these clinical trials is to evaluate the therapeutic effects of
low-level laser energy in pain management, soft tissue trauma and dental
applications. The Company is sponsoring independent research studies of the
MicroLight 830(TM) at various clinical sites in the U.S.
No assurances can be given that (i) the results of the various research
studies that are being or have been conducted using the MicroLight 830(TM), will
demonstrate to the FDA's satisfaction the safety and effectiveness of the
MicroLight 830(TM) in treating CTS, (ii) the FDA will agree that the design of
the studies is satisfactory, (iii) the FDA will not require additional clinical
studies, or (iv) the Company can obtain the necessary FDA marketing clearance
for the MicroLight 830(TM) on a timely basis, if at all. The FDA's rejection of
the clinical design or the data generated could lead to rejection of the
application for commercial marketing of the MicroLight 830(TM) and/or the need
to conduct additional clinical trials.
RISKS OF INTERNATIONAL TRANSACTIONS.
The Company has arrangements with several foreign distributors to
distribute products in Europe, Southeast Asia, the Far East, Central America and
South America. In addition, the Company obtains certain supplies from foreign
suppliers. The acquisition of Enraf-Nonius, if completed, will also
significantly expand the Company's foreign operations. International
transactions subject the Company to several potential risks, including
fluctuating exchange rates (to the extent the Company's transactions are not in
U.S. dollars), regulation of fund transfers by foreign governments, United
States and foreign export and import duties and tariffs and political
instability. There can be no assurance that any of the foregoing will not have a
material adverse effect upon the business of the Company.
Sales of the Company's medical products outside the United States are
subject to regulatory requirements that vary widely from country to country. The
time required to obtain clearance for sale in foreign countries may be longer or
shorter than that required for FDA clearance, and the requirements may differ.
The FDA also regulates the sale of exported medical devices, although to a
lesser extent than devices sold in the United States. For medical products
exported to countries in Europe, the Company anticipates that its customers will
want their products to qualify for distribution under the "CE Mark." The CE Mark
is a designation given to products which comply with certain European Economic
Area policy directives and therefore may be freely traded in almost every
European country. Commencing in 1998, medical product manufacturers will be
required to obtain certifications necessary to enable the CE Mark to be affixed
to medical products they manufacture for sale throughout the European Community.
In addition, the Company's distributors and customers must comply with other
laws generally applicable to foreign trade, including technology export
restrictions, tariffs, and other regulatory barriers. There can be no assurance
that the Company's distributors and customers will obtain all required
clearances or approvals for exported products on a timely basis, if at all.
Failure or delay by the Company's customers in obtaining the requisite
regulatory approvals for exported instruments manufactured by the Company may
have a material adverse effect on the Company's business, results of operations,
and financial condition.
UNCERTAINTY REGARDING PATENTS AND PROPRIETARY INFORMATION.
The Company actively seeks patent protection for its proprietary
technology, both in the U.S. and abroad. The Company owns several U.S. issued
patents and various foreign counterparts. The Company's success will depend, in
part, on its ability to obtain patents and to operate without infringing on the
proprietary rights of others. There can be no assurance that patents issued to
or licensed by the Company will not be challenged, invalidated or circumvented,
or that the rights granted thereunder will provide competitive advantages to the
Company. There can be no assurance that the Company's pending patent
applications or patent applications in preparation presently or in the future,
if and when issued, will be valid and enforceable and withstand litigation.
There can be no assurance that others will not independently develop
substantially equivalent or superseding proprietary technology or that an
equivalent product will not be marketed in competition with the Company's
products, thereby substantially reducing the value of the Company's proprietary
rights. The Company currently has one patent application pending in the U.S.
There is a substantial backlog of patent applications at the U.S. Patent and
Trademark Office ("PTO"). Because patent applications in the U.S. are maintained
in secrecy until patents issue, and because publication of discoveries in the
scientific or patent literature tends to lag behind actual discoveries by
several months, there can be no assurance that the Company will obtain patent
protection for its inventions. In addition, patent protection, even if obtained,
is affected by the limited period of time for which a patent is effective.
Furthermore, patent positions are highly uncertain and involve complex legal and
factual questions. Therefore, the scope or enforceability of claims allowed in
the patents on which the Company will rely cannot be predicted with any
certainty.
The Company also relies on trade secrets, know-how and continuing
technological advancement to maintain its competitive position. Although the
Company has entered into confidentiality agreements with its employees and
consultants, which contain assignment of invention provisions, no assurance can
be given that others will not gain access to these trade secrets, that such
agreements will be honored or that the Company will be able to effectively
protect its rights to its unpatented trade secrets. Moreover, no assurance can
be given that others will not independently develop substantially equivalent
proprietary information and techniques or otherwise gain access to the Company's
trade secrets.
7
<PAGE>
In addition to protecting its proprietary technology and trade secrets,
the Company may be required to obtain licenses to patents or other proprietary
rights from third parties. No assurance can be given that any licenses required
under any patents or proprietary rights would be made available on acceptable
terms, if at all. If the Company does not obtain required licenses, it could
encounter delays in product introductions while it attempts to design around
blocking patents, or it could find that the development, manufacture or sale of
products requiring such licenses could be foreclosed.
Although, the Company has conducted searches to discover any patents which
its products or their use might infringe and is not aware of any such patents,
there can be no assurance that no such infringement has or will occur. The
Company could incur substantial costs in defending any patent infringement suits
or in asserting any patent rights, including those granted by third parties, in
a suit with another party. The PTO could institute interference proceedings
involving the Company in connection with one or more of the Company's patents or
patent applications, and such proceedings could result in an adverse decision as
to priority of invention. The PTO or a comparable agency of a foreign
jurisdiction could also institute re-examination or opposition proceedings
against the Company in connection with one or more of the Company's patents or
patent applications and such proceedings could result in an adverse decision as
to the validity or scope of the patents.
POSSIBLE VOLATILITY OF STOCK PRICE; TRADING MARKET FOR COMMON STOCK.
The stock market has from time to time experienced significant price and
volume fluctuations that may be unrelated to the operating performance of
particular companies. In particular, the market price of the Company's
securities may be highly volatile. Factors such as announcements by the Company
or its competitors concerning acquisitions, technological innovations, new
commercial products or procedures by the Company or its competitors, proposed
governmental regulations and developments in both the U.S. and foreign
countries, disputes relating to patents or proprietary rights, publicity
regarding actual or potential medical results relating to products sold by the
Company or its competitors, public concern as to the safety of these products,
and economic and other external factors, as well as period-to-period
fluctuations and financial results, may have a significant effect on the market
price of the Company's securities.
From time to time, there has been limited trading volume with respect to
the Common Stock. In addition, there can be no assurance that there will
continue to be a trading market or that any analysts will continue to provide
research coverage with respect to the Common Stock. Accordingly, with respect to
the Common Stock being offered hereby, no assurances can be made that such
factors will not affect the market for the Common Stock.
SHARES ELIGIBLE FOR FUTURE SALE; REGISTRATION RIGHTS.
As of December 31, 1997, substantially all of the Company's shares of
Common Stock were eligible for immediate sale in the public market.
Approximately 1,450,000 shares of Common Stock are issuable upon exercise of
employee stock options and will become eligible for sale in the public markets
at prescribed times in the future. The Company's issuances of such 1,450,000
shares are registered on a Form S-8 Registration Statement. As of December 31,
1997, other outstanding options were exercisable to purchase approximately
805,000 shares of Common Stock. In addition, the Series A Preferred Stock is
convertible into a maximum of 862,066 shares of Common Stock (assuming the
Company remains listed on The Nasdaq SmallCap Market), and the Company has
outstanding warrants which are exercisable into an aggregate of 883,776 shares
of Common Stock. Maxxim is the beneficial holder of 1,500,000 shares of Common
Stock which are "restricted securities" under Rule 144(a)(3) of the Securities
Act. Pursuant to a registration rights agreement between the Company and Maxxim,
the Company is obligated to register those shares upon request by Maxxim. In
addition, the holders of approximately 326,852 shares of Common Stock hold
piggy-back registration rights. The issuance of a significant number of shares
of Common Stock upon the exercise of stock options and warrants, the conversion
of the Series A Preferred Stock or the sales of a substantial number of shares
of Common Stock pursuant to Rule 144 or otherwise, could adversely affect the
market price of the Common Stock.
ANTI-TAKEOVER PROVISIONS.
The Company's Certificate of Incorporation and the Texas Business
Corporation Act (the "TBCA") contain certain provisions that may delay or
prevent an attempt by a third-party to acquire control of the Company. In
addition, the severance provisions of employment agreements with certain members
of management could impede an attempted change of control of the Company.
DIVIDENDS.
The Company cannot give any assurance that the proposed operations of the
Company will result in sufficient revenues to enable the Company to operate at a
profitable level. The Company has not paid any dividends on its Common Stock to
date, and has no plans to pay any dividends on its Common Stock for the
foreseeable future. The Company's Series A Preferred Stock accrues a dividend of
4% per year, payable in shares of the Company's Common Stock based on a share
price equal to the closing price of the Company's Common Stock on the Nasdaq on
the particular dividend date.
8
<PAGE>
DISCLOSURE REGARDING FORWARD LOOKING STATEMENTS.
This Prospectus contains certain statements that are "Forward Looking
Statements" within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.
Those statements including, among other things, the discussions of the Company's
business strategy and expectations concerning market position, future
operations, margins, profitability, liquidity and capital resources. Forward
Looking Statements are included in this section under "Future Capital Needs;
Need for Additional Funding," "Management of Growth; Need to Establish
Infrastructure; Additional Personnel," "Increase in Inventory and Trade Accounts
Receivable," "Volatile Markets/Dependence on New Products," "Competition,"
"Limitations on Reimbursement," "Uncertainty Regarding Government Health Care
Reform," "Negative Publicity Regarding TENS," "Product Liability," "Product
Recalls," "Potential Fluctuations in Quarterly Results," "Dependence on Key
Personnel," "Governmental Regulation and FDA Approval," "Risks of International
Transactions," "Uncertainty Regarding Patents and Proprietary Information,"
"Possible Volatility of Stock Price; Trading Market for Common Stock," "Shares
Eligible for Future Sale; Registration Rights," "AntiTakeover Provisions," and
"Dividends." Although the Company believes that the expectations reflected in
Forward Looking Statements are reasonable, they can give no assurance that such
expectations will prove to have been correct. Generally, these statements relate
to business plans or strategies, projected or anticipated benefits or other
consequences of such plans or strategies, or projections involving anticipated
revenues, expenses, earnings, levels of capital expenditures, liquidity or
indebtedness or other aspects of operating results or financial position. All
phases of the operations of the Company are subject to a number of
uncertainties, risks and other influences, many of which are outside the control
of the Company and any one of which, or a combination of which, could materially
affect the results of the Company's operations and whether the Forward Looking
Statements made by the Company ultimately prove to be accurate. Important
factors that could cause actual results to differ materially from the Company's
expectations are disclosed in this "Risk Factors" Section.
9
<PAGE>
SELLING STOCKHOLDERS
The following table sets forth certain information concerning each Selling
Stockholder. The Shares are being registered to permit the Selling Stockholders
and certain of their respective pledgees, donees, transferors or other
successors in interest to offer the Shares for resale from time to time. See
"Plan of Distribution."
<TABLE>
<CAPTION>
NUMBER OF SHARES
OWNED AND TO BE NUMBER OF NUMBER OF SHARES
OWNED PRIOR TO SHARES BEING OWNED AFTER
SELLING STOCKHOLDERS OFFERING (1)(2) OFFERED (2) OFFERING (3)
- ------------------------------------------------------- ------------------- --------------- ------------------
<S> <C> <C> <C>
RBB Bank Aktiengesellschaft ("RBB Bank") (4)........... 169,931 169,931 0
AMRO International S.A. ("AMRO") (4) ............ 424,827 424,827 0
Fourys Co. ("Fourys") (4).............................. 42,482 42,482 0
Bennett Yanowitz ("Yanowitz") (4)...................... 21,241 21,241 0
Reg S Intercontinental Investment, Ltd. ("Reg S") (4).. 53,103 53,103 0
Buntok Holdings S.A. ("Buntok") (4).................... 127,448 127,448 0
The Endeavor Capital Fund S.A. ("Endeavor") (4)........ 223,034 223,034 0
Maxxim Medical, Inc.("Maxxim") (5) .................... 3,000,000 1,500,000 1,500,000
Arkansas Teacher Retirement System..................... 233,000 233,333 0
Columbia Healthcare Corp. Retirement Corp.............. 218,000 218,000 0
Missouri State Employees' Retirement System............ 49,000 49,000 0
Vicky Belcher ("Belcher") (6).......................... 248,148 48,148 200,000
Market Pathways, Inc. (7).............................. 40,000 40,000 0
</TABLE>
(1) The Selling Stockholders have sole voting and sole investment power with
respect to all Shares owned.
(2) Ownership is determined in accordance with Rule 13d-3 under the Exchange
Act. The actual number of Shares beneficially owned and offered for sale
hereunder is subject to adjustment and could be materially less or more
than the estimated account indicated depending upon factors which cannot
be predicted by the Company at this time.
(3) Assumes the sale of all of the Shares offered hereby to persons who are
not affiliates of the Selling Stockholders.
(4) Calculated using the minimum conversion price for the Series A Preferred
Stock of $2.90, subject to adjustment. The number for each of the Selling
Stockholders includes the following number of warrants to purchase Common
Stock: RBB Bank - 32,000; AMRO - 80,000; Fourys - 8,000; Yanowitz - 4,000;
Reg S - 10,000; Buntok - 24,000; and Endeavor - 42,000. Of the warrants
held by RBB, Fourys, Yanowitz, Reg S, Buntok and 68,000 of the warrants
held by AMRO, 25% of such warrants are exercisable at each of $7.125,
$8.194, $8.550 and $9.619, respectively. These warrants expire on March
13, 2003. Of the warrants held by Endeavor and the remaining 12,000
warrants held by AMRO, 25% of such warrants are exercisable at each of
$6.375, $7.331, $7.65 and $8.606, respectively. These warrants expire on
April 9, 2003. The Series A Preferred Stock pays an annual dividend of 4%,
payable quarterly, in cash or shares of Common Stock at the Company's
option. Included in the Prospectus are 30,000 Dividend Shares which are
estimated to be sufficient to meet the Company's obligation to pay
dividends for one year. If all 30,000 Dividend Shares were issued to the
holders of the Series A Preferred Stock, the number for each of the
Selling Stockholders in the table would also include the following number
of Dividend Shares: RBB Bank - 4,800; AMRO - 12,000; Fourys - 1,200;
Yanowitz - 600; Reg S - 1,500; Buntok - 3,600; and Endeavor - 6,300.
(5) The 3,000,000 shares beneficially owned by Maxxim prior to the Offering
includes 1,500,000 shares of Common Stock which are issuable upon
conversion of the $3,000,000 remaining principal on the Maxxim Note which
are not being registered or offered hereby. Interest on the Maxxim Note
currently accrues at a rate of 4% per annum and increases 2% per annum on
each May 1 of each calendar year. Accrued Interest is due and payable on
November 1 and May 1 of each calendar year until May 1, 2003. In addition
to those shares beneficially owned by Maxxim as listed in the table,
Maxxim beneficially owns a number of shares equal to the accrued and
unpaid interest on the Maxxim Note divided by the conversion price under
the Maxxim Note of $2.00(subject to adjustment). As of March 31, 1998,
this would have resulted in Maxxim being deemed to be the beneficial owner
of 51,287 additional shares of Common Stock. Until the Company completes a
public offering, the principal amount of the Maxxim Note is less than $1.5
million or Maxxim owns less than 10% of the outstanding Common Stock, the
Company and certain of its shareholders have agreed to use their best
efforts to have one member of the Board of Directors be chosen by Maxxim.
As of the date of this Prospectus, Maxxim's nominee was Kenneth W.
Davidson, President of Maxxim.
10
<PAGE>
(6) Pursuant to a registration rights agreement between Belcher and the
Company, the Company is obligated to register Belcher's remaining 200,000
shares of Common Stock if at any time it undertakes to register shares of
Common Stock for other selling shareholders in a public offering.
(7) These Shares are issuable upon exercise of an option to purchase that
number of Shares at an exercise price of $4.00 per share (subject to
adjustment). The first 20,000 options will expire on March 12, 1999, and
the remaining 20,000 will expire on September 12, 1999.
PLAN OF DISTRIBUTION
Pursuant to this Prospectus, the Selling Stockholders, or certain
pledgees, donees, transferees or other successors in interest to the Selling
Stockholders, may sell Shares from time to time in transactions on the Nasdaq or
such other exchanges or markets as the Common Stock may be listed for trading
from time to time, in privately-negotiated transactions or by a combination of
such methods of sale, at fixed prices which may be changed, at market prices
prevailing at the time of sale, at prices related to such prevailing market
prices or at negotiated prices. The Selling Stockholders may effect such
transactions by selling the Shares to or through broker-dealers, and such
broker-dealers may receive compensation in the form of discounts, concessions or
commissions from the Selling Stockholders or the purchasers of the Shares for
whom such broker-dealers may act as agent or to whom they sell as principal, or
both (which compensation to a particular broker-dealer might be in excess of
customary commissions).
Other methods by which the Shares may be sold include, without limitation:
(i) transactions which involve cross or block trades or any other transaction
permitted by the Nasdaq or other trading markets, (ii) "at the market" to or
through market makers or into an existing market for the Common Stock, (iii) in
other ways not involving market markers or established trading markets,
including direct sales to purchasers or sales effected through agents, (iv)
through transactions in options or swaps or other derivatives (whether
exchange-listed or otherwise), (v) through short sales, or (vi) any combination
of any such methods of sale. The Selling Stockholders may also enter into option
or other transactions with broker-dealers which require the delivery to such
broker dealers of the Common Stock offered hereby, which Common Stock such
broker-dealers may resell pursuant to this Prospectus. The Selling Shareholders
may also make sales pursuant to Rule 144 under the Securities Act of 1933, as
amended, if such exemption from registration is otherwise available.
The Selling Stockholders and any broker-dealers who act in connection with
the sale of Shares hereunder may be deemed to be "underwriters" as that term is
defined in the Securities Act, and any commissions received by them and profit
on any resale of the Shares as principal might be deemed to be underwriting
discounts and commissions under the Securities Act.
Pursuant to certain Registration Rights Agreements with certain Selling
Stockholders, the Company has agreed to indemnify certain of the Selling
Stockholders and each underwriter against certain liabilities, including certain
liabilities under the Securities Act as amended, or will contribute to payments
such Selling Stockholders or underwriters may be required to make in respect of
certain losses, claims, damages or liabilities.
LEGAL MATTERS
The legality of the securities offered hereby will be passed on for the
Company by Porter & Hedges, L.L.P., Houston, Texas.
EXPERTS
The financial statements as of and for the year ended December 31, 1997
which have been incorporated by reference in this registration statement have
been audited by Arthur Andersen LLP, independent public accountants, as
indicated in their report with respect thereto, and are included herein in
reliance upon the authority of said firm as experts in giving said report. The
financial statements for the year ended December 31, 1996 which have been
incorporated by reference in this registration statement have been audited by
Goldstein, Golub, Kessler & Company, P.C., independent public accountants, as
indicated in their report with respect thereto, and are included herein in
reliance upon the authority of said firm as experts in giving said report.
11
<PAGE>
NO PERSON IS AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
REPRESENTATIONS IN CONNECTION WITH THIS OFFERING OTHER THAN THOSE CONTAINED IN
THIS PROSPECTUS, AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS MUST
NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY. NEITHER THE
DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY
CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE
AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF OR THAT THE INFORMATION CONTAINED
HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO ITS DATE. THIS PROSPECTUS DOES
NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY
SECURITIES IN WHICH IT RELATES. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO
SELL OR A SOLICITATION OF AN OFFER TO BUY SUCH SECURITIES IN ANY CIRCUMSTANCES
IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL.
------------------
TABLE OF CONTENTS
PAGE
----
Available Information.................................2
Incorporation of Certain
Documents by Reference..............................2
The Company...........................................2
Risk Factors..........................................4
Selling Stockholders.................................10
Plan of Distribution.................................11
Legal Matters........................................11
Experts..............................................11
------------------
HENLEY HEALTHCARE, INC.
3,180,214 Shares
of
Common Stock
--------------------
PROSPECTUS
------------------
April 23, 1998
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The estimated expenses payable by the Company in connection with the
offering of the shares of Common Stock to be registered and offered hereby are
as follows:
SEC registration fee........................................ $ 6,274
Legal fees and expenses..................................... 25,000
Blue Sky fees and expenses (including legal expenses)....... 5,000
Accounting fees and expenses................................ 10,000
Miscellaneous............................................... 5,000
--------
Total................................................. $ 51,274
========
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Under Article 1302-7.06 of the Texas Miscellaneous Corporation Laws Act,
the articles of incorporation of a Texas corporation may provide that a director
of that corporation shall not be liable, or shall be liable only to the extent
provided in the articles of incorporation, to the corporation or its
shareholders for monetary damages for acts or omissions in the director's
capacity as a director, except that the articles of incorporation cannot provide
for the elimination or limitation of liability of a director to the extent that
the director is found liable for (i) a breach of the director's duty of loyalty
to the corporation or its shareholders, (ii) an act or omission not in good
faith that constitutes a breach of duty of the director to the corporation or an
act or omission that involves intentional misconduct or a knowing violation of
the law, (iii) any transaction from which the director received an improper
personal benefit, or (iv) an act or omission for which the liability of a
director is expressly provided by an applicable statute.
In accordance with Article 1302-7.06, Article Six of the Company's Amended
and Restated Articles of Incorporation eliminates a director's liability to the
Company and its shareholders for monetary damages for an act or omission in the
director's capacity as a director, except that such provision does not eliminate
or limit a director's liability for: (1) a breach of a director's duty of
loyalty to the Company or its shareholders, (2) an act or omission not in good
faith or that involves intentional misconduct or a knowing violation of law, (3)
a transaction from which a director received an improper benefit, whether or not
the benefit resulted from an action taken within the scope of the director's
office, (4) an act or omission for which the liability of a director is
expressly provided for by statute, or (5) an act related to an unlawful payment
of a dividend. Article Six of the Company's Amended and Restated Articles of
Incorporation further provides that if the Texas Miscellaneous Corporation Laws
Act or any other statute is amended to authorize corporate action further
eliminating or limiting the personal liability of directors, then the liability
of a director of the Company shall be eliminated or limited to the full extent
permitted by such statute, as so amended. If a director breaches any fiduciary
duty other than those listed in Article Six in performing his duties as a
director, neither the Company nor its shareholders could recover monetary
damages from the director; only equitable remedies, such as an action to enjoin
or rescind a transaction involving a breach of fiduciary duty, may be available.
To the extent certain claims against directors are limited to equitable
remedies, the provision in the Company's Amended and Restated Articles of
Incorporation may reduce the likelihood of derivative litigation and may
discourage shareholders or management from initiating litigation against
directors for breach of their fiduciary duties. Additionally, equitable remedies
may not be effective in many situations. If a shareholder's only remedy is to
enjoin the completion of the board of directors' action, such remedy would be
ineffective if the shareholder does not become aware of a transaction or event
until after it has been completed. In such a situation, it is possible that the
Company and its shareholders would have no effective remedy against the
directors.
In addition, Article 2.02-1 of the Texas Business Corporation Act ("TBCA")
empowers the Company to indemnify present and former directors, officers,
employees, agents and other persons acting on the Company's behalf against
judgments, penalties (including excise and similar taxes), fines, settlements
and reasonable expenses (including court costs and attorneys' fees) actually
incurred by them in connection with a proceeding brought against them in their
respective present or former capacities as directors, officers, employees or
agents of the Company, or of any other entity in which they are or were serving
in such capacities at the Company's request. However, the TBCA provides that
unless a court of competent jurisdiction determines otherwise, indemnification
is available only if the person (1) acted in good faith, (2) reasonably believed
that he acted (a) in his official capacity, in a manner which was in the
Company's best interests, and (b) in other than in his official capacity, in a
manner which he reasonably believed was at least not opposed to the Company's
best interests, and (3) in the case of any criminal proceeding, had no
reasonable cause to believe his conduct was unlawful. Even if these three
elements are established, if a person is found liable to the Company, or liable
on the basis that he received
II-1
<PAGE>
an improper personal benefit, indemnification is (i) limited to his reasonable
expenses, and (ii) prohibited if he is found liable for willful or intentional
misconduct in performing his duties to the Company.
The TBCA prescribes procedures which the Company must use in determining
whether a claim is indemnifiable under the statute; if so, whether to authorize
indemnification (unless it is made mandatory by articles of incorporation,
bylaws, director or shareholder resolution, or agreement); and the
reasonableness of any expenses for which indemnification is sought. Each of
these determinations must be made by (i) a majority vote of a quorum of
disinterested directors, (ii) if such quorum is unobtainable, then by a majority
vote of a special committee of disinterested directors appointed by a majority
vote of all directors, (iii) special legal counsel selected by the board of
directors or a committee of the board by vote as described in (i) or (ii), or if
such quorum is unobtainable or such committee cannot be established, then by a
majority vote of all directors, or (iv) a vote of disinterested shareholders.
The Company is obligated under Article 2.02-1 to indemnify a director or
officer against reasonable expenses incurred by him in connection with a
proceeding in which he is named defendant or respondent because he is or was a
director or officer if he has been wholly successful, on the merits or
otherwise, in the defense of the proceeding. Under Article 2.02-1, the Company
may (i) indemnify and advance expenses to an officer, employee, agent or other
person who are or were serving at the request of the Company as a director,
officer, partner venturer, proprietor, trustee, employee, agent or similar
functionary of another entity to the same extent that it may indemnify and
advance expenses to directors, (ii) indemnify and advance expenses to directors
and such other persons to such further extent, consistent with law, as may be
provided in the Company's articles of incorporation, bylaws, action of its board
of directors, or contract or as permitted by common law, and (iii) purchase and
maintain insurance or another arrangement on behalf of directors and such other
persons against any liability asserted against him and incurred by him in such a
capacity or arising out of his status as such a person regardless of whether the
Company could indemnify him against such liability under the TBCA.
Article V of the Company's Amended and Restated Bylaws sets forth specific
provisions for indemnification of directors, officers, agents and other persons
which are substantially identical to the provisions of Article 2.02-1 described
above. The Amended and Restated Bylaws provide for advance payment of any
expenses subject to authorization of the board of directors and a written
promise to repay the payment unless it is determined that he is entitled to
indemnification. Article V further provides that the rights to indemnification
are not exclusive of any other rights to which a person may be entitled by law,
bylaw, agreement, vote of shareholders or otherwise. Such rights to
indemnification by the Amended and Restated Bylaws shall continue after the
person has ceased to hold a position and shall inure to that person's heirs and
personal representatives. The Amended and Restated Bylaws also provide for
reports to the shareholders of the Company as to indemnification payments,
advance payments and insurance payments.
The above discussion of the Company's Amended and Restated Articles of
Incorporation and Amended and Restated Bylaws, as amended, and Texas statutes is
not intended to be exhaustive and is qualified in its entirety by such Articles,
Bylaws and statutes.
The Company maintains officers' and directors' indemnity insurance against
expenses of defending claims or payment of amounts arising out of good-faith
conduct believed by the officer or director to be in or not opposed to the best
interest of the Company. Pursuant to employment agreements entered into by the
Company with its executive officers and certain other key employees, the Company
must indemnify such officers and employees in the same manner and to the same
extent that the Company is required to indemnify its directors under the
Company's Bylaws. In addition, the Company has entered into indemnification
agreements with its officers and directors providing for indemnity to the
maximum extent permitted under the TBCA.
ITEM 16. EXHIBITS.
The following exhibits are filed with this Registration Statement:
EXHIBIT
NUMBER IDENTIFICATION OF EXHIBIT
------ -------------------------
5.1 Opinion of Porter & Hedges, L.L.P.
23.1 Consent of Arthur Andersen LLP
23.2 Consent of Goldstein Golub Kessler & Company, P.C.
23.3 Consent of Porter & Hedges, L.L.P. (included in its Opinion
filed as Exhibit 5.1 hereto).
II-2
<PAGE>
ITEM 17. UNDERTAKINGS.
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by section 10(a)(3) of
the Securities Act;
(ii) To reflect in the prospectus any facts or events arising
after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in
the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high and of the
estimated maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424(b) if, in
the aggregate, the changes in volume and price represent no more than
20 percent change in the maximum aggregate offering price set forth
in the "Calculation or Registration Fee" table in the effective
registration statement;
(iii) To include any material information with respect to the
plan of distribution nor previously disclosed in the registration
statement or any material change to such information in the
registration statement;
provided, however, that paragraphs (1)(i) and (1)(ii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed by the registrant pursuant to
Section 13 or Section 15(d) of the Exchange Act that are incorporated by
reference in the registration statement.
(2) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at
the termination of the offering.
The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange
Act that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions or otherwise, the registrant has
been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.
II-3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Houston, State of Texas, on this 22nd day of April,
1998.
HENLEY HEALTHCARE, INC.
/s/ MICHAEL M. BARBOUR
Michael M. Barbour,
PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR
Each person whose signature appears below hereby appoints Dan D.
Sudduth and Chike J. Ogboenyiya, and both of them, either of whom may act
without the joinder of the other, as his true and lawful attorney-in-fact and
agents, with full power of substitution and resubstitution, for him and in his
name, place and stead, in any and all capacities, to sign any and all amendments
(including post-effective amendments) to this Registration Statement and any
registration statement for the same offering filed pursuant to Rule 462 under
the Securities Act of 1933, and to file the same, with all exhibits thereto and
all other documents in connection therewith, with the Commission, granting unto
said attorney-in-fact and agents full power and authority to do and perform each
and every act and thing appropriate or necessary to be done, as fully and for
all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents or their substitute or
substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities indicated and on this 22nd day of April, 1998.
SIGNATURE TITLE
/s/ MICHAEL M. BARBOUR President, Chief Executive Officer and
- -------------------------- Director
Michael M. Barbour
/s/ DAN D. SUDDUTH Executive Vice President, Chief Financial
- -------------------------- Officer and Director
Dan D. Sudduth
/s/ CHIKE J. OGBOENYIYA Vice President - Finance, Chief Accounting
Chike J. Ogboenyiya Officer and Secretary
__________________________ Medical Director, Chairman of the Board and
Chadwick F. Smith Director
__________________________ Director
Kenneth W. Davidson
/s/ ERNEST J. HENLEY, PH.D. Director
- ---------------------------
Ernest J. Henley, Ph.D.
/s/ PEDRO A. RUBIO, M.D., PH.D. Director
- --------------------------
Pedro A. Rubio, M.D., Ph.D.
II-4
<PAGE>
INDEX TO EXHIBITS
EXHIBIT SEQUENTIAL
NUMBER IDENTIFICATION OF EXHIBIT PAGE NO.
------ ------------------------- --------
5.1 Opinion of Porter & Hedges, L.L.P.
23.1 Consent of Arthur Andersen LLP
23.2 Consent of Goldstein Golub Kessler & Company, P.C.
23.3 Consent of Porter & Hedges, L.L.P. (included in its
Opinion filed as Exhibit 5.1 hereto).
II-5
EXHIBIT 5.1
[PORTER & HEDGES, L.L.P. LETTERHEAD]
April 22, 1998
Henley Healthcare, Inc.
120 Industrial Boulevard
Sugar Land, Texas 77478
Ladies and Gentlemen:
We have acted as counsel to Henley Healthcare, Inc., a Texas
corporation (the "Company"), in connection with the preparation and filing of a
Registration Statement on Form S-3 (the "Registration Statement") with the
Securities and Exchange Commission pursuant to the Securities Act of 1933, as
amended. The Registration Statement relates to an aggregate of 3,180,214 shares
of the Company's common stock, par value $.01 per share (the "Common Stock"),
which may be offered and sold from time to time by selling security holders (the
"Selling Security Holders") of the Company.
We have examined such corporate records, documents, instruments and
certificates of the Company and have received such representations from the
officers and directors of the Company and have reviewed such questions of law as
we have deemed necessary, relevant or appropriate to enable us to render the
opinion expressed herein. In such examination, we have assumed the genuineness
of all signatures and the authenticity of all documents, instruments, records
and certificates submitted to us as originals.
Based on such examination and review and on representations made to us
by the officers and directors of the Company, we are of the opinion that (i) the
862,066 shares of Common Stock to be issued by the Company upon the conversion
of the 2,500 issued and outstanding shares of the Company's Series A Preferred
Stock and offered pursuant to the Registration Statement will be, when so
issued, validly issued, fully-paid and nonassessable outstanding shares of
Common Stock, (ii) the up to 30,000 shares of Common Stock to be issued by the
Company as payment of dividends on the Series A Preferred Stock will be, when so
issued, validly issued, fully-paid and nonassessable outstanding shares of
Common Stock, (iii) the 240,000 shares of Common Stock to be issued by the
Company upon the exercise of certain options and warrants and offered pursuant
to the Registration Statement will be, when so issued, validly issued,
fully-paid and nonassessable outstanding shares of Common Stock, and (iv) the
2,048,148 shares of Common Stock held of record by Maxxim Medical, Inc., the
Institutional Investors and Vicki C. Belcher (the "Med-Quip Share"),
collectively, which are to be offered pursuant to the Registration Statement are
validly issued, fully-paid and nonassessable outstanding shares of Common Stock.
We consent to the use of this opinion as an Exhibit to the Registration
Statement and to the reference to our firm under the heading "Legal Matters" in
the Prospectus included in the Registration Statement.
Very truly yours,
PORTER & HEDGES, L.L.P.
EXHIBIT 23.1
[ARTHUR ANDERSEN LLP LETTERHEAD]
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the
incorporation by reference in this registration statement of our report dated
March 13, 1998 included in Henley Healthcare, Inc.'s Form 10-KSB for the year
ended December 31, 1997, and to all references to our Firm included in this
registration statement.
ARTHUR ANDERSEN LLP
Houston, Texas
April 20, 1998
EXHIBIT 23.2
[GOLDSTEIN GOLUB KESSLER & COMPANY, P.C. LETTERHEAD]
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
We hereby consent to the incorporation by reference in this
registration statement on Form S-3 of our report dated February 23, 1997, on the
consolidated statements of operations stockholder's equity and cash flows for
the year ended December 31, 1996, included in Henley Healthcare, Inc.'s Form
10-KSB for the year ended December 31, 1997, and to the reference to our Firm
under the caption "Experts" in this registration statement.
GOLDSTEIN GOLUB KESSLER & COMPANY, P.C.
New York, New York
April 22, 1998
